Dynavax Technologies Corporation (DVAX)
$15.50+0.00%Close
BUYBULL · day 27
Key stats
- Market cap
- $1.8B
- Beta
- 0.93
- P/E (TTM)
- 39.74
- 1W
- +0.13%
- 1M
- +0.58%
- vs SPY 1W
- +0.27%
- vs SPY 1M
- -1.92%
Industry peers
FMP comparable companies · ranked by market cap
- PLSESELLPulse Biosciences, Inc.$3.6BBEARQ 26$52.45-7.45%
- ELVNSELLEnliven Therapeutics, Inc.$2.9BCRISISQ 11$40.84-3.31%
- PCRXBUYPacira BioSciences, Inc.$1.4BBULLQ 13$36.35-0.11%
- AMPHBUYAmphastar Pharmaceuticals, Inc.$1.2BRECOVERYQ 9$26.76-2.65%
- STAABUYSTAAR Surgical Company$1.1BRECOVERYQ 13$22.01-2.32%
- HROWSELLHarrow Health, Inc.$1.1BCRISISQ 14$29.11-2.99%
- IMTXSELLImmatics N.V.$967MCRISISQ 5$7.21-5.27%
- BBNXSELLBeta Bionics, Inc.$804MCRISISQ -5$17.86-0.95%
- COLLSELLCollegium Pharmaceutical, Inc.$715MBEARQ 14$22.05-2.36%
Prediction markets
Kalshi · Polymarket · … linked
Loading markets…
EARNINGS HISTORY
LOADING…Loading earnings…
Company news
Loading headlines…
FAQ
- What is LOPJLB’s current signal on DVAX?
- LOPJLB’s latest quantitative signal on Dynavax Technologies Corporation (DVAX) is BUY in a BULL regime. Signals are updated daily.
- What market regime is DVAX in?
- Dynavax Technologies Corporation (DVAX) is currently classified in the BULL HMM market regime on LOPJLB.
- What does Dynavax Technologies Corporation (DVAX) do?
- Dynavax Technologies Corporation is a biopharmaceutical firm specializing in the development and market introduction of innovative vaccines, primarily operating in the United States. The company's lead product is HEPLISAV-B, a vaccine approved for adults 18 years and older in the U.S. and Europe, which offers protection against all identified subtypes of the hepatitis B virus. Additionally, Dyn…